EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma

Shuaishuai Xu, Linping Cao, Ruyin Chen, Chanqi Ye, Qiong Li, Qi Jiang, Feifei Yan, Mingyu Wan, Xiaochen Zhang, Jian Ruan

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Shuaishuai Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and In…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Cholangiocarcinoma, Mutation, Bile Duct Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Science and Technology Innovation Medical Development Foundation, National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with intrahepatic cholangiocarcinoma (ICC) are prone to recurrence and poor survival. Targeted therapy related to isocitrate dehydrogenase (IDH) is an extremely important treatment. IDH1 and IDH2 mutations are generally thought to have similar effects on the tumor landscape. However, it is doubtful whether these 2 mutations have exactly the same effects on tumor cells and the tumor microenvironment.

Methods

All collected tumor samples were subjected to simultaneous whole-exon sequencing and proteome sequencing.

Results

IDH1 mutations accounted for 12.2%, and IDH2 mutations accounted for 5.5%, all missense mutations. Tumors with IDH mutations had lower proportions of KRAS and TP53 mutations. Mutated genes were obviously enriched in the kinase pathway in the tumors with IDH2 mutations. The signaling pathways were mainly enriched in the activation of cellular metabolic activities and an increase of inhibitory immune cells in the tumors with IDH mutations. Moreover, tumors had unique enrichment in DNA repair in IDH1 mutants and secretion of biological molecules in IDH2 mutants. Inhibitory immune cells might be more prominent in IDH2 mutants, and the expression of immune checkpoints PVR and HLA-DQB1 was more prominent in IDH1 mutants. IDH mutants were more related to metabolism-related and inflammation-immune response clusters, and some belonged to the DNA replication and repair cluster.

Conclusions

These results revealed the differential IDH1 and IDH2 mutation-related landscapes, and we have provided an important reference database to guide ICC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseCholangiocarcinomaMutationBile Duct NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultTumor Microenvironment

Stichwörter der Autor:innen

intrahepatic cholangiocarcinomaisocitrate dehydrogenaseproteomewhole-exon sequencing

Substanzen

Isocitrate DehydrogenaseIDH2 protein, humanIDH1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, People's Republic of Chin…
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Pub…
  • Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.

Förderung

  • Beijing Science and Technology Innovation Medical Development Foundation
  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Xu, S., Cao, L., Chen, R., Ye, C., Li, Q., Jiang, Q., Yan, F., Wan, M., Zhang, X., & Ruan, J. (2024). Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae132

Vancouver

Xu S, Cao L, Chen R, Ye C, Li Q, Jiang Q, et al. Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. The Oncologist. 2024. doi:10.1093/oncolo/oyae132

BibTeX
@article{Xu2024,
  author = {Xu, Shuaishuai and Cao, Linping and Chen, Ruyin and Ye, Chanqi and Li, Qiong and Jiang, Qi and Yan, Feifei and Wan, Mingyu and Zhang, Xiaochen and Ruan, Jian},
  title = {Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae132}
}
Kostenlos starten →